Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, for all authors except Ram Dessau who reports personal fees from Advisory board meeting 2018, Roche Diagnostics, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Funding Statement

The development of the CUH-NOVO SARS-CoV-2 Total Ab ELISA was financially supported by grants from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (205A0063505).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study of samples from patients with former SARS-CoV-2 infection for validation of serological SARS-CoV-2 assays was approved by the Regional Scientific Committee for the Capital Region of Denmark (H-20028627). All blood donors were asked for consent for using archive samples for their use in the validation of new methods and assay investigations as quality control projects.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes